Oxford-AstraZeneca vaccine is cheaper than Pfizer’s and Moderna’s and doesn’t require supercold temperature
Tuesday, November 24th, 2020Courtesy theconversation.com The biopharmaceutical company AstraZeneca has released data on what is now the third promising vaccine candidate against COVID-19 – and it has several advantages over those of its competitors, Pfizer and Moderna. On Monday, AstraZeneca released interim analysis of its phase 3 trial data of 23,000 volunteers from the U.K. and Brazil. These results show that […]
More >